Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05590468
PHASE2

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

Sponsor: Ralitza Gavrilova

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.

Official title: Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy of Nicotinamide Riboside (NR) - a Vitamin B3 Derivative - for Treatment of Mitochondrial Myopathy Disorder

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

34

Start Date

2023-05-26

Completion Date

2026-11

Last Updated

2026-01-26

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States